UPDATE: See June 23, 2020 article here describing the notable changes. See our article here regarding the final October 2020 Guidelines. On November 23, Innovative Medicines Canada and a number of research-based pharmaceutical companies commenced an application for judicial review of the final Guidelines.
The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.
An industry webinar on the revised draft Guidelines is scheduled for June 29, 2020 from 1:30 – 4:30pm. A public webinar is scheduled for July 8, 2020 from 1:30 to 4:30pm.
The accompanying backgrounder document is to be released by the PMPRB the week of June 22.
Our more detailed reporting of the substantial changes to the first draft of the Guidelines, which were published in November of 2019, will soon follow (see here).
Should you have any questions on the foregoing, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
CDA update: new five-year strategic plan and position statement on using AI in health technology assessments
On April 15, 2025 Canada’s Drug Agency (CDA) released its new five-year strategic plan, Insight to Impact 2025-2030.Read More -
Updated PMPRB Guidelines expected in summer 2025 and NPDUIS releases ninth edition of the Meds Entry Watch Report
In the Patented Medicine Prices Review Board (PMPRB)’s June 2025 NEWSletter, Acting Chairperson Anie Perrault confirms that the PMPRB plans on publishing its final Guidelines in summer 2025.Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More